Efficacy and safety of anlotinib combined with the STUPP regimen in patients with newly diagnosed glioblastoma: a multicenter, single-arm, phase II trial.

Shuzhen LaiPeijing LiXiaohui LiuGuihong LiuTieming XieXing ZhangXiaoxuan WangJing HuangYiqiang TangZhigang LiuGuoping ShenChaoming LiFangxiao LuLei WangFagui JiangCaixing SunYuan-Yuan Chen Ming Chen

Published in: Cancer biology & medicine (2024)

alterations might be novel predictive biomarkers of the response to anlotinib.

Keyphrases

newly diagnosed
open label
cross sectional
double blind
randomized controlled trial